Neurocrine Biosciences, Inc. (NBIX)
148.47
+1.45
(+0.99%)
USD |
NASDAQ |
May 07, 13:24
Neurocrine Biosciences SG&A Expense (TTM) : 879.70M for March 31, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Soleno Therapeutics, Inc. | 132.13M |
| Glaukos Corp. | 354.02M |
| Edgewise Therapeutics, Inc. | 40.02M |
| Nuvalent, Inc. | 107.34M |
| Biogen, Inc. | 2.468B |